Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13).
Authors
Hironaga Satake
Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan
Hironaga Satake , Akihito Tsuji , Chihiro Tanaka , Takao Takahashi , Kunihiko Wakamura , Taichi Yoshida , Kohei Murata , Yoshiaki Shindo , Yasuhide Ishikawa , Ken Konishi , Mitsugu Kochi , Tamotsu Sagawa , Masahito Kotaka , Yutaro Kubota , Yu Sunakawa , Takashi Sekikawa , Masato Nakamura , Masahiro Takeuchi , Wataru Ichikawa , Masashi Fujii
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000018217
DOI
10.1200/JCO.2022.40.4_suppl.109
Abstract #
109
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
First Author: Takanori Watanabe
Poster
2017 Gastrointestinal Cancers Symposium
Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.
First Author: Rachel Lee Delahunty
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel
Poster
2017 Gastrointestinal Cancers Symposium
A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
First Author: Akihito Tsuji